1. Anti-BCMA surface engineered biomimetic photothermal nanomissile enhances multiple myeloma cell apoptosis and overcomes the disturbance of NF-κB signaling in vivo
   Xiaojuan Xiao et al, 2023, Biomaterials CrossRef
2. BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma
   Jiamin Fang et al, 2024, Annals of Hematology CrossRef
3. Cellular membrane-based vesicles displaying a reconstructed B cell maturation antigen for multiple myeloma therapy by dual targeting APRIL and BAFF
   Chao He et al, 2022, Acta Biomaterialia CrossRef
4. BAFF receptor antibody for mantle cell lymphoma therapy
   Keman Zhang et al, 2021, OncoImmunology CrossRef
5. Pathways of Angiogenic and Inflammatory Cytokines in Multiple Myeloma: Role in Plasma Cell Clonal Expansion and Drug Resistance
   Assunta Melaccio et al, 2022, Journal of Clinical Medicine CrossRef
6. Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future
   Hanley N. Abramson, 2023, International Journal of Molecular Sciences CrossRef
7. An Overview of CAR T Cell Mediated B Cell Maturation Antigen Therapy
   Sameer Quazi, 2022, Clinical Lymphoma Myeloma and Leukemia CrossRef
8. Epigenetics of Multiple Myeloma Bone Disease
   Sree H Pulugulla et al, 2019, Current Molecular Biology Reports CrossRef
9. Immunotherapy of Multiple Myeloma: Promise and Challenges
   Hanley N Abramson, 2021, ImmunoTargets and Therapy CrossRef
10. B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma
    Hanley N. Abramson, 2020, International Journal of Molecular Sciences CrossRef
11. B‑cell activating factor receptor expression is associated with germinal center B‑cell maintenance
    Francisco Josu� Carrillo‑Ballesteros et al, 2019, Experimental and Therapeutic Medicine CrossRef
12. Immunological Prognostic Factors in Multiple Myeloma
    Dominika Bębnowska et al, 2021, International Journal of Molecular Sciences CrossRef
13. Obesity and multiple myeloma: Emerging mechanisms and perspectives
    Anastasios Tentolouris et al, 2023, Seminars in Cancer Biology CrossRef
14. Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity
    Yan Sun et al, 2023, Signal Transduction and Targeted Therapy CrossRef
15. BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy
    Barry Paul et al, 2022, Drugs CrossRef
16. Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma
    William Pilcher et al, 2023, npj Genomic Medicine CrossRef
17. BCMA-targeted immunotherapy for multiple myeloma
    Bo Yu et al, 2020, Journal of Hematology & Oncology CrossRef
18. IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma
    Michael D. Pisano et al, 2023, Haematologica CrossRef
19. Emerging Monoclonal Antibodies for the Treatment of Multiple Myeloma
    Hanley N. Abramson, 2021, Monoclonal Antibodies CrossRef
20. The Pathophysiology of Myeloma Bone Disease: Bone Remodelling and the Role of Osteoclasts
    Rebecca E. Andrews et al, 2021, Management of Bone Disease and Kidney Failure in Multiple Myeloma CrossRef
21. Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization
    Nicolas Camviel et al, 2022, Journal for ImmunoTherapy of Cancer CrossRef